NTLA:NSD-Intellia Therapeutics Inc. (USD)

EQUITY | Biotechnology | NASDAQ Global Market

Last Closing

USD 22.38

Change

0.00 (0.00)%

Market Cap

USD 0.61B

Volume

5.39M

Analyst Target

USD 30.15
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+2.53 (+0.54%)

USD 120.95B
REGN Regeneron Pharmaceuticals Inc

+5.99 (+0.57%)

USD 115.81B
MRNA Moderna Inc

-2.80 (-2.36%)

USD 45.51B
ALNY Alnylam Pharmaceuticals Inc

+0.32 (+0.13%)

USD 28.20B
ARGX argenx NV ADR

+4.18 (+0.97%)

USD 26.78B
BNTX BioNTech SE

-1.53 (-1.90%)

USD 20.40B
GMAB Genmab AS

-0.28 (-1.11%)

USD 16.65B
BMRN Biomarin Pharmaceutical Inc

-0.20 (-0.24%)

USD 15.98B
RPRX Royalty Pharma Plc

-0.18 (-0.68%)

USD 15.75B
BGNE BeiGene Ltd

+2.22 (+1.56%)

USD 15.73B

ETFs Containing NTLA

XDNA 8.89 % 0.00 %

N/A

N/A
MSGR 4.67 % 0.00 %

N/A

N/A
ARCG:LSE ARK Genomic Revolution UC.. 4.59 % 0.00 %

+2.40 (+0.70%)

USD 2.30M
ARKG 4.51 % 0.75 %

N/A

N/A
GNOG:LSE Global X Genomics & Biote.. 4.41 % 0.00 %

+0.02 (+0.70%)

USD 6.91M
GN0M:XETRA Global X Genomics & Biote.. 3.90 % 0.00 %

-0.02 (0.70%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 3.90 % 0.00 %

N/A

USD 6.95M
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

-0.03 (0.70%)

USD 0.09B
XSU:CA iShares US Small Cap (CAD.. 0.00 % 0.36 %

N/A

CAD 0.56B
IBBJ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -26.60% 42% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.60% 42% F 25% F
Trailing 12 Months  
Capital Gain -45.12% 41% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -45.12% 41% F 23% F
Trailing 5 Years  
Capital Gain 36.21% 79% B- 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.21% 79% B- 68% D+
Average Annual (5 Year Horizon)  
Capital Gain 96.83% 91% A- 95% A
Dividend Return 96.83% 91% A- 95% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 214.79% 13% F 7% C-
Risk Adjusted Return 45.08% 91% A- 75% C
Market Capitalization 0.61B 91% A- 82% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 115.00 10% 9%
Price/Book Ratio 2.22 58% 44%
Price / Cash Flow Ratio -6.15 71% 78%
Price/Free Cash Flow Ratio -3.04 64% 72%
Management Effectiveness  
Return on Equity -43.60% 72% 34%
Return on Invested Capital -40.74% 65% 25%
Return on Assets -24.15% 65% 22%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector